PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
79.31%
Cash & equivalents growing 79.31% while TRAW's declined -49.30%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
79.31%
Below half of TRAW's -49.30%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.18%
Below half of TRAW's -45.52%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-6.11%
Below half TRAW's -20.95%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.01%
Higher Other Non-Current Assets Growth compared to TRAW's zero value, indicating worse performance.
-0.83%
Below half of TRAW's -18.80%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
67.39%
Below half of TRAW's -45.33%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-6.24%
1.25-1.5x TRAW's -4.31%. Martin Whitman sees potential reliance on supplier financing. Verify liquidity.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-81.40%
Less than half of TRAW's 18.87%. David Dodd sees fewer expansions in other current obligations.
-14.04%
Above 1.5x TRAW's -8.87%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.04%
Above 1.5x TRAW's -4.97%. Michael Burry sees a potential leverage warning sign.
36.75%
Higher Common Stock (Book Value) Growth compared to TRAW's zero value, indicating worse performance.
-4.17%
≥ 1.5x TRAW's -1.99%. David Dodd sees higher yoy retained profits than competitor.
-5.37%
Less than half of TRAW's 90.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
105.08%
Below half TRAW's -1680.41%. Michael Burry sees potential underperformance in building shareholder capital.
67.39%
Below half TRAW's -45.33%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-79.31%
Less than half of TRAW's 49.30%. David Dodd sees better deleveraging or stronger cash buildup than competitor.